Appendix B: Acronyms
| Acronym | Name |
|---|---|
| ACTG | AIDS Clinical Trials Group |
| ANRS | National Agency for AIDS Research (France) |
| ARROW | Anti-retroviral research for Watoto |
| ATHENA | AIDS Therapy Evaluation in the Netherlands |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| ATN | Adolescent Trials Network |
| CHAPAS | Children with HIV in Africa—Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens |
| CHER | Children with HIV Early Antiretroviral Therapy |
| DIONE | A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| FLAIR | First Long-Acting Injectable Regimen |
| HPPM | HIV Paediatric Prognostic Markers |
| HPTN | HIV Prevention Trials Network |
| IMPAACT | International Maternal Pediatric Adolescent AIDS Clinical Trials |
| MOCHA | More Options for Children and Adolescents |
| NEVEREST | Nevirapine Resistance Study |
| PACTG | Pediatric AIDS Clinical Trials Group |
| PENPACT | Trial run in collaboration between PENTA and PACTG/IMPAACT |
| PENTA | Paediatric European Network for Treatment of AIDS |
| PHACS | Pediatric HIV/AIDS Cohort Study |
| PREDICT | Early Versus Deferred Antiretroviral Therapy for Children Older Than 1 Year Infected with HIV |
| PROMOTE | PEPFAR PROMise Ongoing Treatment Evaluation |
| SBIRT | Screening, Brief Intervention, and Referral to Treatment |
| SMILE | Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children |
| START | Strategic Timing of AntiRetroviral Treatment |
Appendix B: Acronyms
| Acronym | Name |
|---|---|
| ACTG | AIDS Clinical Trials Group |
| ANRS | National Agency for AIDS Research (France) |
| ARROW | Anti-retroviral research for Watoto |
| ATHENA | AIDS Therapy Evaluation in the Netherlands |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| ATN | Adolescent Trials Network |
| CHAPAS | Children with HIV in Africa—Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens |
| CHER | Children with HIV Early Antiretroviral Therapy |
| DIONE | A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| FLAIR | First Long-Acting Injectable Regimen |
| HPPM | HIV Paediatric Prognostic Markers |
| HPTN | HIV Prevention Trials Network |
| IMPAACT | International Maternal Pediatric Adolescent AIDS Clinical Trials |
| MOCHA | More Options for Children and Adolescents |
| NEVEREST | Nevirapine Resistance Study |
| PACTG | Pediatric AIDS Clinical Trials Group |
| PENPACT | Trial run in collaboration between PENTA and PACTG/IMPAACT |
| PENTA | Paediatric European Network for Treatment of AIDS |
| PHACS | Pediatric HIV/AIDS Cohort Study |
| PREDICT | Early Versus Deferred Antiretroviral Therapy for Children Older Than 1 Year Infected with HIV |
| PROMOTE | PEPFAR PROMise Ongoing Treatment Evaluation |
| SBIRT | Screening, Brief Intervention, and Referral to Treatment |
| SMILE | Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children |
| START | Strategic Timing of AntiRetroviral Treatment |
Download Guidelines
- Section OnlyPDF (79.99 KB)
- Full GuidelinePDF (5.84 MB)
- Recommendations OnlyPDF (849.58 KB)
- Tables OnlyPDF (1.77 MB)
- Drug Tables OnlyPDF (2.74 MB)